#### **GILEAD SCIENCES INC**

Form 4 June 05, 2013

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

**OMB APPROVAL** 

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person MARTIN JOHN C	* 2. Issuer Name and Ticker or Trading Symbol GILEAD SCIENCES INC [GILD]	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)		
(Last) (First) (Middle)	3. Date of Earliest Transaction	(eneck an approacte)		
	(Month/Day/Year)	X Director 10% Owner		
GILEAD SCIENCES, INC., 333	06/03/2013	X Officer (give title Other (specify below)		
LAKESIDE DRIVE		Chairman and CEO		
(Street)	4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
	Filed(Month/Day/Year)	Applicable Line)		
FOSTER CITY, CA 94404		_X_ Form filed by One Reporting Person Form filed by More than One Reporting		
1 Object Ciri, CA 74404		Person		

(City)	(State)	(Zip) Tal	ole I - Non-	-Derivative	Securi	ities Acquire	ed, Disposed of, o	or Beneficially	Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securitie orDisposed o (Instr. 3, 4	f (D)	uired (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/03/2013		M	282,242	A		4,339,363	D	
Common Stock	06/03/2013		S	28,200	D	\$ 51.912 (3)	4,311,163	D	
Common Stock	06/03/2013		S	225,700	D	\$ 52.7984 (4)	4,085,463	D	
Common Stock	06/03/2013		S	24,800	D	\$ 53.992 (5)	4,060,663	D	
Common Stock	06/03/2013		S	3,542	D	\$ 54.5884	4,057,121	D	

#### Edgar Filing: GILEAD SCIENCES INC - Form 4

(6)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Title and A Underlying S (Instr. 3 and	Secui
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Am Nu Sha
Non-Qualified Stock option (right to buy)	\$ 7.6325	06/03/2013		M <u>(1)</u>	282,242	(2)	01/28/2014	Common Stock	28

### **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
MARTIN JOHN C							
GILEAD SCIENCES, INC.	X		Chairman and CEO				
333 LAKESIDE DRIVE	Λ		Chairman and CEO				
FOSTER CITY, CA 94404							

### **Signatures**

/s/ John C.
Martin

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- (2) The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- (3) Sale prices reported for the transactions reported here range from \$51.42 to \$52.42. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

Reporting Owners 2

### Edgar Filing: GILEAD SCIENCES INC - Form 4

- (4) Sale prices reported for the transactions reported here range from \$52.43 to \$53.41. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- (5) Sale prices reported for the transactions reported here range from \$53.46 to \$54.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- (6) Sale prices reported for the transactions reported here range from \$54.55 to \$54.59. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.